← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
151	OBX 151 Obsidian Therapeutics OBX $728M	–	–	–	–
152	152 Ocugen OCGN $274M	–	–	–	–
153	153 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	–	–	–	–
154	154 DELISTED Singular Genomics Systems, Inc. Common Stock OMIC	–	–	–	–
155	ONCS 155 DELISTED OncoSec Medical Incorporated ONCS	–	–	–	–
156	156 DELISTED Orgenesis Inc. Common Stock ORGS	–	–	–	–
157	ORTX 157 DELISTED Orchard Therapeutics plc American Depositary Shares ORTX	–	–	–	–
158	158 Passage Bio PASG $11.1M	–	–	–	–
159	159 PepGen PEPG $176M	–	–	–	–
160	160 PharmaCyte Biotech PMCB $3.8M	–	–	–	–
161	161 Prime Medicine PRME $637M	–	–	–	–
162	162 ProKidney PROK $276M	–	–	–	–
163	163 Personalis PSNL $1.66B	–	–	–	–
164	164 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
165	165 Quantum-Si Incorporated QSI $247M	–	–	–	–
166	166 Rocket Pharmaceuticals RCKT $245M	–	–	–	–
167	RCOR 167 DELISTED Renovacor, Inc. RCOR	–	–	–	–
168	168 Regenxbio RGNX $457M	–	–	–	–
169	169 Atrium Therapeutics RNA $132M	–	–	–	–
170	170 Cartesian Therapeutics RNAC $191M	–	–	–	–
171	RUBY 171 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
172	172 Sana Biotechnology SANA $686M	–	–	–	–
173	SCPS 173 DELISTED Scopus BioPharma Inc. Common Stock SCPS	–	–	–	–
174	SCTX 174 Scribe Therapeutics Inc SCTX $376M	–	–	–	–
175	SGTX 175 DELISTED Sigilon Therapeutics, Inc. Common Stock SGTX	–	–	–	–